For broader research context on nootropic compounds, including comparative stacks, cycling considerations, and interaction notes, see the Complete Nootropic Cheat Sheet.
What Is DSIP?
Delta Sleep Inducing Peptide (DSIP) is a nonapeptide first isolated from cerebral venous blood of rabbits in a state of slow-wave sleep in 1974. Despite its name, DSIP has since been found to exert a remarkably diverse range of biological effects across neuroendocrine, cardiovascular, and stress-response systems.
Sleep Regulation
DSIP's founding property — induction of delta (slow-wave) sleep — is mediated through interactions with the sleep regulatory system. It modulates hypothalamic sleep centers, interacts with serotonergic and opioidergic systems governing sleep-wake cycling, and has been shown to reduce sleep latency and increase the proportion of deep non-REM sleep. Unlike pharmacological sleep aids, it does not produce sedation during waking hours or rebound insomnia.
Stress and Opioid Withdrawal Research
DSIP demonstrates capacity to normalize cortisol secretion and attenuate stress-induced HPA axis responses — generating research interest for stress-related sleep disorders. One of the more striking applications is attenuation of opioid withdrawal symptoms: studies in both animal models and small human trials have shown DSIP reduces withdrawal severity, potentially through interactions with endogenous opioid receptor systems and stress-axis normalization.
Quick Reference
Member reference tables summarize the compound's research parameters.
Research Indications
Research Protocols
As reported in cited literature and research-community logs (see Research Citations below), not a personal dosing recommendation.
This member section describes parameters reported in the research literature.
Peptide Interactions
This member section summarizes reported compound interactions and evidence limitations.
Reported Research Time Points
This member section summarizes reported research time points.
Safety Notes
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
This member section discusses research safety considerations and uncertainties.
Quality Indicators
Research Citations
- Stroke Recovery in Rats (2021)
Rats | 120 μg/kg nasal | 7 days | Enhanced motor recovery - Chronic Insomnia Double-Blind Study (1991)
Human | 15-30 nmol | 6 consecutive nights | Improved sleep efficiency - Endocrine Modulation Research (1988)
Human/Animal | Various doses | Multiple studies | Hormone regulation - Chronic Pain Pilot Study (1984)
Human | 25 nmol IV | 10 days | 6/7 patients improved - Alcohol and Opioid Withdrawal (1984)
Human | Variable doses | 5-10 days | Symptom reduction - Sleep Pressure Induction Study (1983)
Human | 25 nmol/kg IV | Single dose | 59% sleep increase - Delta sleep-inducing peptide (DSIP): a still unresolved riddle
Kovalzon VM, Strekalova TV, 2006, J Neurochem - Delta-sleep-inducing peptide (DSIP): an update
Graf MV, Kastin AJ, 1986, Peptides - The effect of delta sleep-inducing peptide (DSIP) and phosphorylated DSIP (P-DSIP) on the apomorphine-induced hypothermia in rats
Tsunashima K, Masui A, Kato N, 1990, Brain Res - Pichia pastoris secreted peptides crossing the blood-brain barrier and DSIP fusion peptide efficacy in PCPA-induced insomnia mouse models
Mu X, Qu L, Yin L, 2024, Front Pharmacol - Delta sleep-inducing peptide (DSIP)-like immunoreactivity in gut: coexistence with known peptide hormones
Bjartell A, Ekman R, Hedenbro J, 1989, Peptides